Use of 2-deoxy-2-[F-18]-fluoro-D-glucose positron emission tomography to monitor therapeutic response by rhabdomyosarcoma in children: Report of a retrospective case study

Clinical Nuclear Medicine

Volumn 31, Issue 7, 2006, Pages 394-397

  Peng, Fangyu ^a   Rabkin, Galina ^a   Muzik, Otto ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 deoxy 2 F 18 fluoro D glucose; Pediatrics; Positron emission tomography; Rhabdomyosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CHILD; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INFORMATION RETRIEVAL; MALE; MEDICAL DOCUMENTATION; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; TREATMENT RESPONSE;

CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; JAW NEOPLASMS; LUNG NEOPLASMS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PARANASAL SINUS NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SKULL NEOPLASMS;

EID: 33748206270     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000222954.38724.be     Document Type: Article

References (15)

1. Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution by age, sex and location. AJR Am J Roentgenol. 1995;164:129-134.
2. Pappo AS. Rhabdomyosarcoma and other soft tissue sarcomas in children. Curr Opin Oncol. 1996;8:311-316.
3. Raney RB Jr, Tefft M, Hays DM, et al. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott; 1993:769-794.
4. Enzinger FM, Weiss SW. Rhabdomyosarcoma. In: Enzinger FM, Weiss SW, eds. Soft Tissue Tumors, 3rd ed. St. Louis: Mosby; 1995:539-577.
5. Pappo AS, Shapiro DN, Crist WM, et al. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol. 1995;13:2123-2139.
6. Sohaib SA, Moseley I, Wright JE. Orbital rhabdomyosarcoma and the radiological characteristics. Clin Radiol. 1998;53:357-362.
7. Donaldson SS, Anderson J. Factors that influence treatment decisions in childhood rhabdomyosarcoma. Radiology. 1997;203:17-22.
8. Gilles R, Couanet D, Chevret S, et al. Importance of the post-therapeutic residue in the prognosis of head and neck rhabdomyosarcoma in children. Eur J Radiol. 1991;13:187-191.
9. Young H, Brock C. Wells and Price monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography (PET). Drug Information Journal. 1999;33:237-244.
10. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nature Reviews Cancer. 2002;2:683-693.
11. Shulkin BL. PET applications in pediatrics. Q J Nucl Med. 1997;41:281-291.
12. Shulkin B, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology. 1995;194:495-500.
13. McCarville BM, Christie R, Daw NC, et al. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol. 2005;184:1293-1304.
14. Chin BB, Lyengar S, Sabundayo BP, et al. Standardized uptake values in 2-deoxy-2-[F-18]-DG with PET. Clinical significance of iterative reconstruction and segmented attenuation compared with conventional FBP and measured attenuation correction. Mol Imaging Biol. 2002;4:294-300.
15. Kim EE, Valenzuela RF, Kumar AJ, et al. Imaging and clinical spectrum of rhabdomyosarcoma in children. Clin Imaging. 2000;24:257-262.